Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates.

Milani M, Annoni A, Moalli F, Liu T, Cesana D, Calabria A, Bartolaccini S, Biffi M, Russo F, Visigalli I, Raimondi A, Patarroyo-White S, Drager D, Cristofori P, Ayuso E, Montini E, Peters R, Iannacone M, Cantore A, Naldini L.

Sci Transl Med. 2019 May 22;11(493). pii: eaav7325. doi: 10.1126/scitranslmed.aav7325.

PMID:
31118293
2.

Assessing the Impact of Cyclosporin A on Lentiviral Transduction and Preservation of Human Hematopoietic Stem Cells in Clinically Relevant Ex Vivo Gene Therapy Settings.

Petrillo C, Calabria A, Piras F, Capotondo A, Spinozzi G, Cuccovillo I, Benedicenti F, Naldini L, Montini E, Biffi A, Gentner B, Kajaste-Rudnitski A.

Hum Gene Ther. 2019 May 24. doi: 10.1089/hum.2019.016. [Epub ahead of print]

PMID:
31037976
3.

Precise Gene Editing Preserves Hematopoietic Stem Cell Function following Transient p53-Mediated DNA Damage Response.

Schiroli G, Conti A, Ferrari S, Della Volpe L, Jacob A, Albano L, Beretta S, Calabria A, Vavassori V, Gasparini P, Salataj E, Ndiaye-Lobry D, Brombin C, Chaumeil J, Montini E, Merelli I, Genovese P, Naldini L, Di Micco R.

Cell Stem Cell. 2019 Apr 4;24(4):551-565.e8. doi: 10.1016/j.stem.2019.02.019. Epub 2019 Mar 21.

4.

Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia.

Marktel S, Scaramuzza S, Cicalese MP, Giglio F, Galimberti S, Lidonnici MR, Calbi V, Assanelli A, Bernardo ME, Rossi C, Calabria A, Milani R, Gattillo S, Benedicenti F, Spinozzi G, Aprile A, Bergami A, Casiraghi M, Consiglieri G, Masera N, D'Angelo E, Mirra N, Origa R, Tartaglione I, Perrotta S, Winter R, Coppola M, Viarengo G, Santoleri L, Graziadei G, Gabaldo M, Valsecchi MG, Montini E, Naldini L, Cappellini MD, Ciceri F, Aiuti A, Ferrari G.

Nat Med. 2019 Feb;25(2):234-241. doi: 10.1038/s41591-018-0301-6. Epub 2019 Jan 21.

PMID:
30664781
5.

Multiple Integrated Non-clinical Studies Predict the Safety of Lentivirus-Mediated Gene Therapy for β-Thalassemia.

Lidonnici MR, Paleari Y, Tiboni F, Mandelli G, Rossi C, Vezzoli M, Aprile A, Lederer CW, Ambrosi A, Chanut F, Sanvito F, Calabria A, Poletti V, Mavilio F, Montini E, Naldini L, Cristofori P, Ferrari G.

Mol Ther Methods Clin Dev. 2018 Sep 13;11:9-28. doi: 10.1016/j.omtm.2018.09.001. eCollection 2018 Dec 14.

6.

De(bar)coding aged hematopoiesis in primates.

Di Micco R, Montini E.

Blood. 2018 Mar 15;131(11):1157-1159. doi: 10.1182/blood-2018-02-826412. No abstract available.

7.

VISPA2: a scalable pipeline for high-throughput identification and annotation of vector integration sites.

Spinozzi G, Calabria A, Brasca S, Beretta S, Merelli I, Milanesi L, Montini E.

BMC Bioinformatics. 2017 Nov 25;18(1):520. doi: 10.1186/s12859-017-1937-9.

8.

HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells.

Cesana D, Santoni de Sio FR, Rudilosso L, Gallina P, Calabria A, Beretta S, Merelli I, Bruzzesi E, Passerini L, Nozza S, Vicenzi E, Poli G, Gregori S, Tambussi G, Montini E.

Nat Commun. 2017 Sep 8;8(1):498. doi: 10.1038/s41467-017-00609-1.

9.

Lentiviral Vector Promoter is Decisive for Aberrant Transcript Formation.

Scholz SJ, Fronza R, Bartholomä CC, Cesana D, Montini E, von Kalle C, Gil-Farina I, Schmidt M.

Hum Gene Ther. 2017 Oct;28(10):875-885. doi: 10.1089/hum.2017.162. Epub 2017 Aug 18.

PMID:
28825370
10.

Different Polyubiquitinated Bodies in Human Dendritic Cells: IL-4 Causes PaCS During Differentiation while LPS or IFNα Induces DALIS During Maturation.

Montagna D, Sommi P, Necchi V, Vitali A, Montini E, Turin I, Ferraro D, Ricci V, Solcia E.

Sci Rep. 2017 May 12;7(1):1844. doi: 10.1038/s41598-017-02090-8.

11.

Preclinical Testing of the Safety and Tolerability of Lentiviral Vector-Mediated Above-Normal Alpha-L-Iduronidase Expression in Murine and Human Hematopoietic Cells Using Toxicology and Biodistribution Good Laboratory Practice Studies.

Visigalli I, Delai S, Ferro F, Cecere F, Vezzoli M, Sanvito F, Chanut F, Benedicenti F, Spinozzi G, Wynn R, Calabria A, Naldini L, Montini E, Cristofori P, Biffi A.

Hum Gene Ther. 2016 Oct;27(10):813-829. doi: 10.1089/hum.2016.068.

PMID:
27431943
12.

Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.

Magnani CF, Turazzi N, Benedicenti F, Calabria A, Tenderini E, Tettamanti S, Giordano Attianese GM, Cooper LJ, Aiuti A, Montini E, Biondi A, Biagi E.

Oncotarget. 2016 Aug 9;7(32):51581-51597. doi: 10.18632/oncotarget.9955.

13.

miRNA-126 Orchestrates an Oncogenic Program in B Cell Precursor Acute Lymphoblastic Leukemia.

Nucera S, Giustacchini A, Boccalatte F, Calabria A, Fanciullo C, Plati T, Ranghetti A, Garcia-Manteiga J, Cittaro D, Benedicenti F, Lechman ER, Dick JE, Ponzoni M, Ciceri F, Montini E, Gentner B, Naldini L.

Cancer Cell. 2016 Jun 13;29(6):905-921. doi: 10.1016/j.ccell.2016.05.007.

14.

Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial.

Sessa M, Lorioli L, Fumagalli F, Acquati S, Redaelli D, Baldoli C, Canale S, Lopez ID, Morena F, Calabria A, Fiori R, Silvani P, Rancoita PM, Gabaldo M, Benedicenti F, Antonioli G, Assanelli A, Cicalese MP, Del Carro U, Sora MG, Martino S, Quattrini A, Montini E, Di Serio C, Ciceri F, Roncarolo MG, Aiuti A, Naldini L, Biffi A.

Lancet. 2016 Jul 30;388(10043):476-87. doi: 10.1016/S0140-6736(16)30374-9. Epub 2016 Jun 8.

PMID:
27289174
15.

Safe and Efficient Gene Therapy for Pyruvate Kinase Deficiency.

Garcia-Gomez M, Calabria A, Garcia-Bravo M, Benedicenti F, Kosinski P, López-Manzaneda S, Hill C, Del Mar Mañu-Pereira M, Martín MA, Orman I, Vives-Corrons JL, Kung C, Schambach A, Jin S, Bueren JA, Montini E, Navarro S, Segovia JC.

Mol Ther. 2016 Aug;24(7):1187-98. doi: 10.1038/mt.2016.87. Epub 2016 May 3.

16.

Pervasive supply of therapeutic lysosomal enzymes in the CNS of normal and Krabbe-affected non-human primates by intracerebral lentiviral gene therapy.

Meneghini V, Lattanzi A, Tiradani L, Bravo G, Morena F, Sanvito F, Calabria A, Bringas J, Fisher-Perkins JM, Dufour JP, Baker KC, Doglioni C, Montini E, Bunnell BA, Bankiewicz K, Martino S, Naldini L, Gritti A.

EMBO Mol Med. 2016 May 2;8(5):489-510. doi: 10.15252/emmm.201505850. Print 2016 May.

17.

adLIMS: a customized open source software that allows bridging clinical and basic molecular research studies.

Calabria A, Spinozzi G, Benedicenti F, Tenderini E, Montini E.

BMC Bioinformatics. 2015;16 Suppl 9:S5. doi: 10.1186/1471-2105-16-S9-S5. Epub 2015 Jun 1.

18.

Shedding of clinical-grade lentiviral vectors is not detected in a gene therapy setting.

Cesani M, Plati T, Lorioli L, Benedicenti F, Redaelli D, Dionisio F, Biasco L, Montini E, Naldini L, Biffi A.

Gene Ther. 2015 Jun;22(6):496-502. doi: 10.1038/gt.2015.10. Epub 2015 Mar 12.

PMID:
25762283
19.

Liver-directed lentiviral gene therapy in a dog model of hemophilia B.

Cantore A, Ranzani M, Bartholomae CC, Volpin M, Valle PD, Sanvito F, Sergi LS, Gallina P, Benedicenti F, Bellinger D, Raymer R, Merricks E, Bellintani F, Martin S, Doglioni C, D'Angelo A, VandenDriessche T, Chuah MK, Schmidt M, Nichols T, Montini E, Naldini L.

Sci Transl Med. 2015 Mar 4;7(277):277ra28. doi: 10.1126/scitranslmed.aaa1405.

20.

In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells.

Biasco L, Scala S, Basso Ricci L, Dionisio F, Baricordi C, Calabria A, Giannelli S, Cieri N, Barzaghi F, Pajno R, Al-Mousa H, Scarselli A, Cancrini C, Bordignon C, Roncarolo MG, Montini E, Bonini C, Aiuti A.

Sci Transl Med. 2015 Feb 4;7(273):273ra13. doi: 10.1126/scitranslmed.3010314.

PMID:
25653219
21.

VISPA: a computational pipeline for the identification and analysis of genomic vector integration sites.

Calabria A, Leo S, Benedicenti F, Cesana D, Spinozzi G, Orsini M, Merella S, Stupka E, Zanetti G, Montini E.

Genome Med. 2014 Sep 3;6(9):67. doi: 10.1186/s13073-014-0067-5. eCollection 2014.

22.

Cyclosporin a and rapamycin relieve distinct lentiviral restriction blocks in hematopoietic stem and progenitor cells.

Petrillo C, Cesana D, Piras F, Bartolaccini S, Naldini L, Montini E, Kajaste-Rudnitski A.

Mol Ther. 2015 Feb;23(2):352-62. doi: 10.1038/mt.2014.193. Epub 2014 Oct 1.

23.

Lentiviral vector-based insertional mutagenesis identifies genes involved in the resistance to targeted anticancer therapies.

Ranzani M, Annunziato S, Calabria A, Brasca S, Benedicenti F, Gallina P, Naldini L, Montini E.

Mol Ther. 2014 Dec;22(12):2056-68. doi: 10.1038/mt.2014.174. Epub 2014 Sep 8.

24.

Targeted genome editing in human repopulating haematopoietic stem cells.

Genovese P, Schiroli G, Escobar G, Tomaso TD, Firrito C, Calabria A, Moi D, Mazzieri R, Bonini C, Holmes MC, Gregory PD, van der Burg M, Gentner B, Montini E, Lombardo A, Naldini L.

Nature. 2014 Jun 12;510(7504):235-240. doi: 10.1038/nature13420. Epub 2014 May 28.

25.

Case report: long-lasting response in a patient with metastatic renal cell cancer receiving antitumor cytotoxic T lymphocytes.

Secondino S, Turin I, Montini E, Porta C, Maccario R, Pedrazzoli P, Montagna D.

Tumori. 2013 Nov-Dec;99(6):282e-4e. doi: 10.1700/1390.15469.

PMID:
24503804
26.

Therapeutic benefit of lentiviral-mediated neonatal intracerebral gene therapy in a mouse model of globoid cell leukodystrophy.

Lattanzi A, Salvagno C, Maderna C, Benedicenti F, Morena F, Kulik W, Naldini L, Montini E, Martino S, Gritti A.

Hum Mol Genet. 2014 Jun 15;23(12):3250-68. doi: 10.1093/hmg/ddu034. Epub 2014 Jan 23.

27.

Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo.

Cesana D, Ranzani M, Volpin M, Bartholomae C, Duros C, Artus A, Merella S, Benedicenti F, Sergi Sergi L, Sanvito F, Brombin C, Nonis A, Serio CD, Doglioni C, von Kalle C, Schmidt M, Cohen-Haguenauer O, Naldini L, Montini E.

Mol Ther. 2014 Apr;22(4):774-85. doi: 10.1038/mt.2014.3. Epub 2014 Jan 20.

28.

Wiskott-Aldrich syndrome protein deficiency in natural killer and dendritic cells affects antitumor immunity.

Catucci M, Zanoni I, Draghici E, Bosticardo M, Castiello MC, Venturini M, Cesana D, Montini E, Ponzoni M, Granucci F, Villa A.

Eur J Immunol. 2014 Apr;44(4):1039-45. doi: 10.1002/eji.201343935. Epub 2014 Jan 13.

29.

Cancer gene discovery: exploiting insertional mutagenesis.

Ranzani M, Annunziato S, Adams DJ, Montini E.

Mol Cancer Res. 2013 Oct;11(10):1141-58. doi: 10.1158/1541-7786.MCR-13-0244. Epub 2013 Aug 8. Review.

30.

Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy.

Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, Baldoli C, Martino S, Calabria A, Canale S, Benedicenti F, Vallanti G, Biasco L, Leo S, Kabbara N, Zanetti G, Rizzo WB, Mehta NA, Cicalese MP, Casiraghi M, Boelens JJ, Del Carro U, Dow DJ, Schmidt M, Assanelli A, Neduva V, Di Serio C, Stupka E, Gardner J, von Kalle C, Bordignon C, Ciceri F, Rovelli A, Roncarolo MG, Aiuti A, Sessa M, Naldini L.

Science. 2013 Aug 23;341(6148):1233158. doi: 10.1126/science.1233158. Epub 2013 Jul 11.

31.

Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome.

Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C, Dionisio F, Calabria A, Giannelli S, Castiello MC, Bosticardo M, Evangelio C, Assanelli A, Casiraghi M, Di Nunzio S, Callegaro L, Benati C, Rizzardi P, Pellin D, Di Serio C, Schmidt M, Von Kalle C, Gardner J, Mehta N, Neduva V, Dow DJ, Galy A, Miniero R, Finocchi A, Metin A, Banerjee PP, Orange JS, Galimberti S, Valsecchi MG, Biffi A, Montini E, Villa A, Ciceri F, Roncarolo MG, Naldini L.

Science. 2013 Aug 23;341(6148):1233151. doi: 10.1126/science.1233151. Epub 2013 Jul 11.

32.

Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer.

Ranzani M, Cesana D, Bartholomae CC, Sanvito F, Pala M, Benedicenti F, Gallina P, Sergi LS, Merella S, Bulfone A, Doglioni C, von Kalle C, Kim YJ, Schmidt M, Tonon G, Naldini L, Montini E.

Nat Methods. 2013 Feb;10(2):155-61. doi: 10.1038/nmeth.2331. Epub 2013 Jan 13.

33.

The fetal mouse is a sensitive genotoxicity model that exposes lentiviral-associated mutagenesis resulting in liver oncogenesis.

Nowrouzi A, Cheung WT, Li T, Zhang X, Arens A, Paruzynski A, Waddington SN, Osejindu E, Reja S, von Kalle C, Wang Y, Al-Allaf F, Gregory L, Themis M, Holder M, Dighe N, Ruthe A, Buckley SM, Bigger B, Montini E, Thrasher AJ, Andrews R, Roberts TP, Newbold RF, Coutelle C, Schmidt M, Themis M.

Mol Ther. 2013 Feb;21(2):324-37. doi: 10.1038/mt.2012.224. Epub 2012 Nov 13.

34.

Brain conditioning is instrumental for successful microglia reconstitution following hematopoietic stem cell transplantation.

Capotondo A, Milazzo R, Politi LS, Quattrini A, Palini A, Plati T, Merella S, Nonis A, di Serio C, Montini E, Naldini L, Biffi A.

Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):15018-23. doi: 10.1073/pnas.1205858109. Epub 2012 Aug 23.

35.

Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy.

Corrigan-Curay J, Cohen-Haguenauer O, O'Reilly M, Ross SR, Fan H, Rosenberg N, Somia N, King N, Friedmann T, Dunbar C, Aiuti A, Naldini L, Baum C, von Kalle C, Kiem HP, Montini E, Bushman F, Sorrentino BP, Carrondo M, Malech H, Gahrton G, Shapiro R, Wolff L, Rosenthal E, Jambou R, Zaia J, Kohn DB.

Mol Ther. 2012 Jun;20(6):1084-94. doi: 10.1038/mt.2012.93. No abstract available.

36.

Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations.

Cesana D, Sgualdino J, Rudilosso L, Merella S, Naldini L, Montini E.

J Clin Invest. 2012 May;122(5):1667-76. doi: 10.1172/JCI62189. Epub 2012 Apr 23.

37.

Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndrome.

Scaramuzza S, Biasco L, Ripamonti A, Castiello MC, Loperfido M, Draghici E, Hernandez RJ, Benedicenti F, Radrizzani M, Salomoni M, Ranzani M, Bartholomae CC, Vicenzi E, Finocchi A, Bredius R, Bosticardo M, Schmidt M, von Kalle C, Montini E, Biffi A, Roncarolo MG, Naldini L, Villa A, Aiuti A.

Mol Ther. 2013 Jan;21(1):175-84. doi: 10.1038/mt.2012.23. Epub 2012 Feb 28. Erratum in: Mol Ther. 2016 Jun;24(6):1159.

38.

Genotoxicity assay for gene therapy vectors in tumor prone Cdkn2a⁻/⁻ mice.

Montini E, Cesana D.

Methods Enzymol. 2012;507:171-85. doi: 10.1016/B978-0-12-386509-0.00009-0.

PMID:
22365774
39.

Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor.

Montagna D, Turin I, Schiavo R, Montini E, Zaffaroni N, Villa R, Secondino S, Schiavetto I, Caliogna L, Locatelli F, Libri V, Pession A, Tonelli R, Maccario R, Siena S, Pedrazzoli P.

Cytotherapy. 2012 Jan;14(1):80-90. doi: 10.3109/14653249.2011.610303. Epub 2011 Sep 23.

PMID:
21942841
40.

Quest for safety at AAValon.

Montini E.

Blood. 2011 Mar 24;117(12):3249-50. doi: 10.1182/blood-2011-02-321984. No abstract available.

41.

Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection.

Biffi A, Bartolomae CC, Cesana D, Cartier N, Aubourg P, Ranzani M, Cesani M, Benedicenti F, Plati T, Rubagotti E, Merella S, Capotondo A, Sgualdino J, Zanetti G, von Kalle C, Schmidt M, Naldini L, Montini E.

Blood. 2011 May 19;117(20):5332-9. doi: 10.1182/blood-2010-09-306761. Epub 2011 Mar 14.

42.

Lentiviral vector integration profiles differ in rodent postmitotic tissues.

Bartholomae CC, Arens A, Balaggan KS, Yáñez-Muñoz RJ, Montini E, Howe SJ, Paruzynski A, Korn B, Appelt JU, Macneil A, Cesana D, Abel U, Glimm H, Naldini L, Ali RR, Thrasher AJ, von Kalle C, Schmidt M.

Mol Ther. 2011 Apr;19(4):703-10. doi: 10.1038/mt.2011.19. Epub 2011 Mar 1.

43.

Relevance of an academic GMP Pan-European vector infra-structure (PEVI).

Cohen-Haguenauer O, Creff N, Cruz P, Tunc C, Aïuti A, Baum C, Bosch F, Blomberg P, Cichutek K, Collins M, Danos O, Dehaut F, Federspiel M, Galun E, Garritsen H, Hauser H, Hildebrandt M, Klatzmann D, Merten OW, Montini E, O'Brien T, Panet A, Rasooly L, Scherman D, Schmidt M, Schweitzer M, Tiberghien P, Vandendriessche T, Ziehr H, Ylä-Herttuala S, von Kalle C, Gahrton G, Carrondo M.

Curr Gene Ther. 2010 Dec;10(6):414-22.

PMID:
21054249
44.

Chromosomal integration of adenoviral vector DNA in vivo.

Stephen SL, Montini E, Sivanandam VG, Al-Dhalimy M, Kestler HA, Finegold M, Grompe M, Kochanek S.

J Virol. 2010 Oct;84(19):9987-94. doi: 10.1128/JVI.00751-10. Epub 2010 Aug 4.

45.

Comprehensive genomic access to vector integration in clinical gene therapy.

Gabriel R, Eckenberg R, Paruzynski A, Bartholomae CC, Nowrouzi A, Arens A, Howe SJ, Recchia A, Cattoglio C, Wang W, Faber K, Schwarzwaelder K, Kirsten R, Deichmann A, Ball CR, Balaggan KS, Yáñez-Muñoz RJ, Ali RR, Gaspar HB, Biasco L, Aiuti A, Cesana D, Montini E, Naldini L, Cohen-Haguenauer O, Mavilio F, Thrasher AJ, Glimm H, von Kalle C, Saurin W, Schmidt M.

Nat Med. 2009 Dec;15(12):1431-6. doi: 10.1038/nm.2057. Epub 2009 Nov 22.

PMID:
19966782
46.

Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy.

Cassani B, Montini E, Maruggi G, Ambrosi A, Mirolo M, Selleri S, Biral E, Frugnoli I, Hernandez-Trujillo V, Di Serio C, Roncarolo MG, Naldini L, Mavilio F, Aiuti A.

Blood. 2009 Oct 22;114(17):3546-56. doi: 10.1182/blood-2009-02-202085. Epub 2009 Aug 3.

47.

The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy.

Montini E, Cesana D, Schmidt M, Sanvito F, Bartholomae CC, Ranzani M, Benedicenti F, Sergi LS, Ambrosi A, Ponzoni M, Doglioni C, Di Serio C, von Kalle C, Naldini L.

J Clin Invest. 2009 Apr;119(4):964-75. doi: 10.1172/JCI37630. Epub 2009 Mar 23.

48.

Unaltered repopulation properties of mouse hematopoietic stem cells transduced with lentiviral vectors.

Gonzalez-Murillo A, Lozano ML, Montini E, Bueren JA, Guenechea G.

Blood. 2008 Oct 15;112(8):3138-47. doi: 10.1182/blood-2008-03-142661. Epub 2008 Aug 6.

49.

Interleukin-15 favors the expansion of central memory CD8+ T cells in ex vivo generated, antileukemia human cytotoxic T lymphocyte lines.

Daudt L, Maccario R, Locatelli F, Turin I, Silla L, Montini E, Percivalle E, Giugliani R, Avanzini MA, Moretta A, Montagna D.

J Immunother. 2008 May;31(4):385-93. doi: 10.1097/CJI.0b013e31816b1092.

PMID:
18391757
50.

Targeted inactivation of the COP9 signalosome impairs multiple stages of T cell development.

Panattoni M, Sanvito F, Basso V, Doglioni C, Casorati G, Montini E, Bender JR, Mondino A, Pardi R.

J Exp Med. 2008 Feb 18;205(2):465-77. doi: 10.1084/jem.20070725. Epub 2008 Feb 11.

Supplemental Content

Loading ...
Support Center